Treatment-Induced Acute Leukaemia after Major Response to Cyclophosphamide-Based Metronomic Chemotherapy in Refractory Heavily Pre-Treated Prostate Cancer
- 1 Department of Medical Oncology, University Hospital of Besan?on, Besan?on, France
- 2 Department of Medical Oncology, University Hospital of Besan?on, Besan?on, France
- 3 Department of Medical Oncology, University Hospital of Besan?on, Besan?on, France
- 4 Department of Medical Oncology, University Hospital of Besan?on, Besan?on, France
- 5 Institut National de la Santé et de la Recherche Médicale-Unité Mixte de Recherche (INSERM UMR) No. 1098, Besan?on, France
- 6 Department of Medical Oncology, University Hospital of Besan?on, Besan?on, France
Abstract
Background: metronomic chemotherapy is based on antiangiogenic and immunologic mechanisms obtained by the administration of traditional cytotoxic drugs at lower concentration without rest periods. The low dosage induces fewer or no side effect compared to classic maximum tolerated dose administration (MTD). At present, no treatment related acute leukaemia was reported in cyclophosphamide-based metronomic chemotherapy (CMC). Case: We report the case of an 81-year-old man considered as having castration and chemo-refractory metastatic prostate cancer. CMC was started. Objective response was observed in this heavily pre-treated patient with progression free survival lasting more than 30 months. No toxicity was observed in this period and his autonomy was maintained. Finally, our patient developed a chemotherapy-induced acute myeloid leukaemia at 36th month of CMC. Conclusion: Even CMC is a well- t oler at ed treatment; secondary acute leukaemia is related to cumulative dose of cyclophosphamide. The benefit and the risk of long-term exposure to cyclophosphamide should be carefully balanced.
- http://www.cancer.gov/dictionary?cdrid=546597
- R. S. Kerbel and B. A. Kamen, “The Anti-Angiogenic Basis of Metronomic Chemotherapy,” Nature, Vol. 4, No. 6, 2004, pp. 423-436.
- D. Hanahan, G. Bergers and E. Bergsland, “Less is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice,” Journal of Clinical Investigation, Vol. 105, No. 8, 2000, pp. 1045-1047. doi:10.1172/JCI9872
- S. Man, G. Bocci, G. Francia, S. K. Green, S. Jothy, D. Hanahan, et al., “Antitumor Effects in Mice of Low-Dose (Metronomic) Cyclophosphamide Administered Continuously through the Drinking Water,” Cancer Research, Vol. 62, No. 10, 2002, pp. 2731-2735.
- Y. Hamano, H. Sugimoto, M. A. Soubasakos, M. Kieran, B. R. Olsen, J. Lawler, et al., “Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression,” Cancer Research, Vol. 64, No. 5, 2004, p. 1570. doi:10.1158/0008-5472.CAN-03-3126
- J. E. Damber, C. Vallbo, P. Albertsson, B. Lennernas and K. Norrby, “The Anti-Tumour Effect of Low-Dose Continuous Chemotherapy May Partly Be Mediated by Thrombospondin,” Cancer Chemotherapy and Pharmacology, Vol. 58, No. 3, 2006, pp. 354-360. doi:10.1007/s00280-005-0163-8
- M. E. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom and H. Sabzevari, “Inhibition of CD4(_)25_T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-Dose Cyclophosphamide,” Blood, Vol. 105, No. 7, 2005, pp. 2862-2868. doi:10.1182/blood-2004-06-2410
- J. Mayer, M. Krejcí, M. Doubek, Z. Pospísil, Y. Brychtová, et al., “Pulse Cyclophosphamide for Corticoid -Refractory Graft-Versus-Host Disease,” Bone Marrow Transplantation, Vol. 35, No. 7, 2005, pp. 699-705. doi:10.1038/sj.bmt.1704829
- A. Reiner, T. Gernsheimer and S. J. Slichter, “Pulse Cyclophosphamide Therapy for Refractory Autoimmune Thrombocytopenic Purpura,” Blood, Vol. 85, No. 2, 1995, pp. 351-358.
- N. Penel, A. Adenis and G. Bocci, “Cyclophosphamide-Based Metronomic Chemotherapy: After 10 Years of Experience, Where Do We Stand and Where Are We Going?” Critical Reviews in Oncology/Hematology, Vol. 82, No. 1, 2011, pp. 40-50.
- M. Colleoni, A. Rocca, M. T. Sandri, et al., “Low-Dose Oral Methotrexate and Cyclophosphamide in Metastatic Breast Cancer: Antitumor Activity and Correlation with Vascular Endothelial Growth Factor Levels,” Annals of Oncology, Vol. 13, No. 1, 2002, pp. 73-80. doi:10.1093/annonc/mdf013